Akèy › Maladi fwa steatotik › Kalifòni
Etid klinik pou Maladi fwa steatotik nan Kalifòni
22 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- San Diego14 etid
- Los Angeles8 etid
- Pasadena8 etid
- Lancaster7 etid
- Orange5 etid
- Fresno5 etid
- Huntington Beach5 etid
- San Francisco5 etid
- Rialto5 etid
- Long Beach4 etid
- Folsom4 etid
- Simi Valley3 etid
- Sacramento3 etid
- Escondido3 etid
- Santa Maria3 etid
Tèks ofisyèl etid la (Anglè)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Folsom
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Folsom
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Southern California Research Center, Coronado
- California Liver Research Institute, Pasadena
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- University of California San Diego NAFLD Research Center, La Jolla
- Keck Medical Center of USC, Los Angeles
- LAC + USC Medical Center, Los Angeles
- ak 2 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Southern California Research Center, Coronado
- Om Research Llc, Lancaster
- Clinnova Research Solutions, Orange
- ak 3 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- San Fernando Valley Health Institute, Canoga Park
- Ark Clinical Research - Fountain Valley, Fountain Valley
- Fresno Clinical Research Center, Fresno
- ak 11 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Coronado
- Akero Clinical Study Site, Escondido
- Akero Clinical Study Site, Folsom
- ak 13 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Arcadia
- GSK Investigational Site, Covina
- GSK Investigational Site, Los Angeles
- ak 3 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Om Research, Apple Valley
- ARK Clinical Research - Fountain Valley, Fountain Valley
- UCSD Medical Center, La Jolla
- ak 4 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Canoga Park
- 89bio Clinical Study Site, Coronado
- 89bio Clinical Study Site, Escondido
- ak 13 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Camarillo
- 89bio Clinical Study Site, Canoga Park
- 89bio Clinical Study Site, Coronado
- ak 10 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Coronado
- GSK Investigational Site, Lancaster
- GSK Investigational Site, Los Angeles
- ak 3 plis
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Arcadia
- GSK Investigational Site, Covina
- GSK Investigational Site, Folsom
- ak 6 plis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fresno
- GSK Investigational Site, Lancaster
- GSK Investigational Site, Pasadena
- ak 2 plis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 8, 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, Rialto
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 9, 2026 · NCT07358546Bicalutamide Therapy in Young Women With NAFLD and PCOS
- University of California San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 a 42 · Fanm · Mizajou May 29, 2026 · NCT05979389A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Velocity Clinical research, Los Angeles
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Apr 16, 2026 · NCT05648214Androgens and NAFLD Longitudinal Cohort Study
- University of California San Francisco, San Francisco
Ap rekriteEtid obsèvasyon
Laj 18 a 42 · Fanm · Mizajou Apr 13, 2026 · NCT06124261Accurate Point of Care Liver Disease Diagnostics (Phase 2)
- University of California San Diego, La Jolla
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT07518784Quantitative Ultrasound to Assess Steatotic Liver Disease in Children
- University of California San Diego, La Jolla
Ap rekriteEtid obsèvasyon
Laj 9 a 18 · Tout sèks · Mizajou Jan 21, 2026 · NCT06706856Implementing Food Referrals for Equity and Sustained Health
- Rady Children's Hospital San Diego, San Diego
Ap rekriteFaz 2Volontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Nov 19, 2025 · NCT06661538Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
- Stanford University, Stanford
Ap rekriteVolontè an sante akeyi
Laj 35 a 65 · Tout sèks · Mizajou Dec 4, 2024 · NCT05165706Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.